Open-Label Extension Study of Trofinetide for Rett Syndrome
Study sponsor: ACADIA Pharmaceuticals Inc. · ACAD
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-06-30Actual
Enrollment · participants77Actual
Source updated2024-09-27Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.